Biotech company Alnylam Pharmaceuticals conceded defeat for now in a lawsuit against Pfizer and BioNTech over technology in ...

The European Court of Justice Wednesday ruled there was no plausible reason to block the New York Times from getting European ...

A top European court says the European Commission failed to provide a credible explanation for refusing The New York Times ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

China said on Wednesday it would further enhance capital market support for science and technology innovation enterprises and ...

After 6 months, placebo was associated with a mean weight gain of 0.4 kg (o.88 lb), compared with 1.2-1.9 kg (2.6-4.2 lb) ...

Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.